

Ioana Braicu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/170992/publications.pdf>

Version: 2024-02-01

50
papers

1,698
citations

279798

23
h-index

289244

40
g-index

50
all docs

50
docs citations

50
times ranked

3796
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. <i>Oncotarget</i> , 2016, 7, 1486-1499.	1.8	212
2	An Illegitimate microRNA Target Site within the 3' UTR of <i>MDM4</i> Affects Ovarian Cancer Progression and Chemosensitivity. <i>Cancer Research</i> , 2010, 70, 9641-9649.	0.9	152
3	GPCR-specific autoantibody signatures are associated with physiological and pathological immune homeostasis. <i>Nature Communications</i> , 2018, 9, 5224.	12.8	116
4	Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance – A study of the OVCAD consortium. <i>Gynecologic Oncology</i> , 2013, 128, 15-21.	1.4	107
5	Prognostic Value of Residual Tumor Size in Patients With Epithelial Ovarian Cancer FIGO Stages IIA–IV: Analysis of the OVCAD Data. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 380-385.	2.5	91
6	Value of Tertiary Cytoreductive Surgery in Epithelial Ovarian Cancer: An International Multicenter Evaluation. <i>Annals of Surgical Oncology</i> , 2013, 20, 1348-1354.	1.5	64
7	Validating the impact of a molecular subtype in ovarian cancer on outcomes: A study of the OVCAD Consortium. <i>Cancer Science</i> , 2012, 103, 1334-1341.	3.9	59
8	Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients – A study of the OVCAD consortium. <i>European Journal of Cancer</i> , 2014, 50, 99-110.	2.8	53
9	Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer. <i>British Journal of Cancer</i> , 2018, 119, 1060-1066.	6.4	47
10	Outcome and Clinical Management of 275 Patients With Advanced Ovarian Cancer International Federation of Obstetrics and Gynecology II to IV Inside the European Ovarian Cancer Translational Research Consortium – OVCAD. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 268-275.	2.5	46
11	MALDI-imaging for Classification of Epithelial Ovarian Cancer Histotypes from a Tissue Microarray Using Machine Learning Methods. <i>Proteomics - Clinical Applications</i> , 2019, 13, e1700181.	1.6	45
12	Association of myeloperoxidase with ovarian cancer. <i>Tumor Biology</i> , 2014, 35, 141-148.	1.8	43
13	Neutrophil Granulocytes in Ovarian Cancer - Induction of Epithelial-To-Mesenchymal-Transition and Tumor Cell Migration. <i>Journal of Cancer</i> , 2016, 7, 546-554.	2.5	42
14	Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium. <i>Journal of Ovarian Research</i> , 2013, 6, 42.	3.0	41
15	Somatic copy number alterations predict response to platinum therapy in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 135, 415-422.	1.4	38
16	Fibroblast growth factor receptor 4 gene (<i>FGFR4</i>) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer. <i>International Journal of Cancer</i> , 2012, 131, E586-91.	5.1	29
17	A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer - a study of the OVCAD consortium. <i>BMC Cancer</i> , 2013, 13, 178.	2.6	29
18	Fertility-Sparing Surgery in Early Epithelial Ovarian Cancer: A Viable Option?. <i>Obstetrics and Gynecology International</i> , 2012, 2012, 1-8.	1.3	28

#	ARTICLE	IF	CITATIONS
19	Somatic Copy Number Alterations Associated with Japanese or Endometriosis in Ovarian Clear Cell Adenocarcinoma. <i>PLoS ONE</i> , 2015, 10, e0116977.	2.5	28
20	HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy. <i>Gynecologic Oncology</i> , 2018, 149, 155-162.	1.4	27
21	Wilms tumor protein 1 (WT1) – Not only a diagnostic but also a prognostic marker in high-grade serous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2016, 140, 494-502.	1.4	26
22	A Meta-Analysis on the Impact of Platinum-Based Adjuvant Treatment on the Outcome of Borderline Ovarian Tumors With Invasive Implants. <i>Oncologist</i> , 2015, 20, 151-158.	3.7	25
23	tRNAGlyGCC-Derived Internal Fragment (i-tRF-GlyGCC) in Ovarian Cancer Treatment Outcome and Progression. <i>Cancers</i> , 2022, 14, 24.	3.7	25
24	Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer. <i>Neoplasia</i> , 2018, 20, 280-288.	5.3	23
25	Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer – A Study of the GANNET53 Consortium. <i>Frontiers in Oncology</i> , 2019, 9, 832.	2.8	23
26	Plasma concentrations of the vitamin E-binding protein afamin are associated with overall and progression-free survival and platinum sensitivity in serous ovarian cancer – a study by the OVCAD consortium. <i>Gynecologic Oncology</i> , 2013, 128, 38-43.	1.4	22
27	Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre study. <i>British Journal of Cancer</i> , 2017, 116, 1287-1293.	6.4	22
28	Mutational profiles of Brenner tumors show distinctive features uncoupling urothelial carcinomas and ovarian carcinoma with transitional cell histology. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 758-766.	2.8	21
29	Interferon-stimulated Gene, 15 kDa (ISG15) in Ovarian High-grade Serous Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2014, 33, 16-22.	1.4	20
30	The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns. <i>Epigenetics</i> , 2013, 8, 1226-1235.	2.7	19
31	AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer. <i>BMC Genomics</i> , 2016, 17, 643.	2.8	19
32	Long-term follow-up of borderline ovarian tumors clinical outcome and prognostic factors. <i>Anticancer Research</i> , 2014, 34, 6725-30.	1.1	17
33	Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab. <i>Oncotarget</i> , 2015, 6, 25017-25023.	1.8	14
34	Ambivalent role of pFAK-Y397 in serous ovarian cancer-a study of the OVCAD consortium. <i>Molecular Cancer</i> , 2014, 13, 67.	19.2	13
35	Integrated transcriptomic and proteomic analysis identifies protein kinase CK2 as a key signaling node in an inflammatory cytokine network in ovarian cancer cells. <i>Oncotarget</i> , 2016, 7, 15648-15661.	1.8	13
36	Duration of storage influences the hemoglobin rising effect of red blood cells in patients undergoing major abdominal surgery. <i>Transfusion</i> , 2018, 58, 1870-1880.	1.6	13

#	ARTICLE	IF	CITATIONS
37	Transfusion of red blood cells does not impact progression-free and overall survival after surgery for ovarian cancer. <i>Transfusion</i> , 2019, 59, 3589-3600.	1.6	13
38	PDK1 is Expressed in Ovarian Serous Carcinoma and Correlates with Improved Survival in High-grade Tumors. <i>Anticancer Research</i> , 2015, 35, 6329-34.	1.1	13
39	Limited efficacy of platinum-based adjuvant treatment on the outcome of borderline ovarian tumors. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2015, 186, 26-33.	1.1	12
40	miR-203 is an independent molecular predictor of prognosis and treatment outcome in ovarian cancer: a multi-institutional study. <i>Carcinogenesis</i> , 2020, 41, 442-451.	2.8	10
41	Expression, Intracellular Localization, and Prognostic Value of Plasminogen Activator Inhibitor 1 and PAI-1 RNA-Binding Protein 1 in Primary and Recurrent Ovarian Cancer: A Study of the Tumor Bank Ovarian Cancer Network. <i>Gynecologic and Obstetric Investigation</i> , 2018, 83, 508-514.	1.6	7
42	miR-181a overexpression predicts the poor treatment response and early progression of serous ovarian cancer patients. <i>International Journal of Cancer</i> , 2020, 147, 3560-3573.	5.1	7
43	New <i>in vitro</i> system to predict chemotherapeutic efficacy of drug combinations in fresh tumor samples. <i>PeerJ</i> , 2017, 5, e3030.	2.0	6
44	Prediction of clinical response to drugs in ovarian cancer using the chemotherapy resistance test (CTR-test). <i>Journal of Ovarian Research</i> , 2017, 10, 72.	3.0	5
45	Primary platinum resistance and its prognostic impact in patients with recurrent ovarian cancer: an analysis of three prospective trials from the NOGGO study group. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e37.	2.2	5
46	Characteristics of homologous recombination deficiency (HRD) in paired primary and recurrent high-grade serous ovarian cancer (HGSOC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 5534-5534.	1.6	3
47	Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 143-151.	2.8	2
48	Soluble heat-shock protein 27 in blood serum is a non-invasive prognostic biomarker for ovarian cancer. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 255, 154-159.	1.1	2
49	Interval versus primary tumor debulking surgery in advanced ovarian cancer: Analysis of the European OVCAD data.. <i>Journal of Clinical Oncology</i> , 2012, 30, 5071-5071.	1.6	1
50	Detection of soluble EpCAM in malignant ascites to predict overall survival in patients treated with catumaxomab.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15173-e15173.	1.6	0